PCN68 Brigatinib Compared with Crizotinib and Alectinib in Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases at Diagnosis: A Cost-Effectiveness Analysis from the Perspective of the Brazilian Private Health ...
Abstract
Authors
I. Genov B. Mendes da Silva G.M. Lanchoti Fiori B. Villas Boas T. Teixeira Chadid C. Regis